ASAP Score versus GALAD Score for detection of hepatitis C-related hepatocellular carcinoma: A multicenter case-control analysis

The GALAD and ASAP scores are two well-recognized algorithms to estimate the risk of hepatocellular carcinoma (HCC) based on gender, age, alpha-fetoprotein (AFP), protein induced by vitamin K absence or Antagonist-II (PIVKA-II) and AFP-L3 (included in the GALAD score but not in the ASAP score). The...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 12; p. 1018396
Main Authors Liu, Si-Yu, Li, Chao, Sun, Li-Yang, Guan, Ming-Cheng, Gu, Li-Hui, Yin, Dong-Xu, Yao, Lan-Qing, Liang, Lei, Wang, Ming-Da, Xing, Hao, Zhu, Hong, Pawlik, Timothy M., Lau, Wan Yee, Shen, Feng, Tong, Xiang-Min, Yang, Tian
Format Journal Article
LanguageEnglish
Published Frontiers Media S.A 30.09.2022
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The GALAD and ASAP scores are two well-recognized algorithms to estimate the risk of hepatocellular carcinoma (HCC) based on gender, age, alpha-fetoprotein (AFP), protein induced by vitamin K absence or Antagonist-II (PIVKA-II) and AFP-L3 (included in the GALAD score but not in the ASAP score). The current study sought to compare the diagnostic performance of each score to detect HCC among patients infected with hepatitis C virus (HCV).BackgroundThe GALAD and ASAP scores are two well-recognized algorithms to estimate the risk of hepatocellular carcinoma (HCC) based on gender, age, alpha-fetoprotein (AFP), protein induced by vitamin K absence or Antagonist-II (PIVKA-II) and AFP-L3 (included in the GALAD score but not in the ASAP score). The current study sought to compare the diagnostic performance of each score to detect HCC among patients infected with hepatitis C virus (HCV).A multicenter case-control study was undertaken in which blood samples were collected from HCVinfected patients with and without HCC. Using the area under the receiver operating characteristic curve (AUROC), ASAP and GALAD scores were compared relative to diagnostic performance to detect any stage HCV-HCC and early-stage HCV-HCC.MethodsA multicenter case-control study was undertaken in which blood samples were collected from HCVinfected patients with and without HCC. Using the area under the receiver operating characteristic curve (AUROC), ASAP and GALAD scores were compared relative to diagnostic performance to detect any stage HCV-HCC and early-stage HCV-HCC.The analytic cohort included 168 HCV-HCC patients and a control group of 193 HCV-infected patients. The ASAP score had a higher AUROC to detect any stage HCV-HCC versus the GALAD score, both in the overall group (0.917 vs. 0.894, P=0.057) and in the cirrhosis subgroup (0.909 vs. 0.889, P=0.132). Similar results were noted relative to the detection of early-stage HCV-HCC, whether defined by BCLC staging (stage 0-A: 0.898 vs. 0.860, P=0.026) or 8th TNM staging (stage I: 0.899 vs. 0.870, P=0.070). In subgroup analysis to detect AFP-negative HCV-HCC, the ASAP score also demonstrated a higher AUROC than the GALAD score to detect any stage HCV-HCC in the AFP-negative subgroup (0.815 vs. 0.764, P=0.063).ResultsThe analytic cohort included 168 HCV-HCC patients and a control group of 193 HCV-infected patients. The ASAP score had a higher AUROC to detect any stage HCV-HCC versus the GALAD score, both in the overall group (0.917 vs. 0.894, P=0.057) and in the cirrhosis subgroup (0.909 vs. 0.889, P=0.132). Similar results were noted relative to the detection of early-stage HCV-HCC, whether defined by BCLC staging (stage 0-A: 0.898 vs. 0.860, P=0.026) or 8th TNM staging (stage I: 0.899 vs. 0.870, P=0.070). In subgroup analysis to detect AFP-negative HCV-HCC, the ASAP score also demonstrated a higher AUROC than the GALAD score to detect any stage HCV-HCC in the AFP-negative subgroup (0.815 vs. 0.764, P=0.063).The ASAP score had better diagnostic performance for early detection of HCV-HCC compared with the GALAD score. The ASAP score may be preferrable to the GALAD score for HCC screening and surveillance among HCV-infected patients.ConclusionsThe ASAP score had better diagnostic performance for early detection of HCV-HCC compared with the GALAD score. The ASAP score may be preferrable to the GALAD score for HCC screening and surveillance among HCV-infected patients.
AbstractList The GALAD and ASAP scores are two well-recognized algorithms to estimate the risk of hepatocellular carcinoma (HCC) based on gender, age, alpha-fetoprotein (AFP), protein induced by vitamin K absence or Antagonist-II (PIVKA-II) and AFP-L3 (included in the GALAD score but not in the ASAP score). The current study sought to compare the diagnostic performance of each score to detect HCC among patients infected with hepatitis C virus (HCV).BackgroundThe GALAD and ASAP scores are two well-recognized algorithms to estimate the risk of hepatocellular carcinoma (HCC) based on gender, age, alpha-fetoprotein (AFP), protein induced by vitamin K absence or Antagonist-II (PIVKA-II) and AFP-L3 (included in the GALAD score but not in the ASAP score). The current study sought to compare the diagnostic performance of each score to detect HCC among patients infected with hepatitis C virus (HCV).A multicenter case-control study was undertaken in which blood samples were collected from HCVinfected patients with and without HCC. Using the area under the receiver operating characteristic curve (AUROC), ASAP and GALAD scores were compared relative to diagnostic performance to detect any stage HCV-HCC and early-stage HCV-HCC.MethodsA multicenter case-control study was undertaken in which blood samples were collected from HCVinfected patients with and without HCC. Using the area under the receiver operating characteristic curve (AUROC), ASAP and GALAD scores were compared relative to diagnostic performance to detect any stage HCV-HCC and early-stage HCV-HCC.The analytic cohort included 168 HCV-HCC patients and a control group of 193 HCV-infected patients. The ASAP score had a higher AUROC to detect any stage HCV-HCC versus the GALAD score, both in the overall group (0.917 vs. 0.894, P=0.057) and in the cirrhosis subgroup (0.909 vs. 0.889, P=0.132). Similar results were noted relative to the detection of early-stage HCV-HCC, whether defined by BCLC staging (stage 0-A: 0.898 vs. 0.860, P=0.026) or 8th TNM staging (stage I: 0.899 vs. 0.870, P=0.070). In subgroup analysis to detect AFP-negative HCV-HCC, the ASAP score also demonstrated a higher AUROC than the GALAD score to detect any stage HCV-HCC in the AFP-negative subgroup (0.815 vs. 0.764, P=0.063).ResultsThe analytic cohort included 168 HCV-HCC patients and a control group of 193 HCV-infected patients. The ASAP score had a higher AUROC to detect any stage HCV-HCC versus the GALAD score, both in the overall group (0.917 vs. 0.894, P=0.057) and in the cirrhosis subgroup (0.909 vs. 0.889, P=0.132). Similar results were noted relative to the detection of early-stage HCV-HCC, whether defined by BCLC staging (stage 0-A: 0.898 vs. 0.860, P=0.026) or 8th TNM staging (stage I: 0.899 vs. 0.870, P=0.070). In subgroup analysis to detect AFP-negative HCV-HCC, the ASAP score also demonstrated a higher AUROC than the GALAD score to detect any stage HCV-HCC in the AFP-negative subgroup (0.815 vs. 0.764, P=0.063).The ASAP score had better diagnostic performance for early detection of HCV-HCC compared with the GALAD score. The ASAP score may be preferrable to the GALAD score for HCC screening and surveillance among HCV-infected patients.ConclusionsThe ASAP score had better diagnostic performance for early detection of HCV-HCC compared with the GALAD score. The ASAP score may be preferrable to the GALAD score for HCC screening and surveillance among HCV-infected patients.
BackgroundThe GALAD and ASAP scores are two well-recognized algorithms to estimate the risk of hepatocellular carcinoma (HCC) based on gender, age, alpha-fetoprotein (AFP), protein induced by vitamin K absence or Antagonist-II (PIVKA-II) and AFP-L3 (included in the GALAD score but not in the ASAP score). The current study sought to compare the diagnostic performance of each score to detect HCC among patients infected with hepatitis C virus (HCV).MethodsA multicenter case-control study was undertaken in which blood samples were collected from HCVinfected patients with and without HCC. Using the area under the receiver operating characteristic curve (AUROC), ASAP and GALAD scores were compared relative to diagnostic performance to detect any stage HCV-HCC and early-stage HCV-HCC.ResultsThe analytic cohort included 168 HCV-HCC patients and a control group of 193 HCV-infected patients. The ASAP score had a higher AUROC to detect any stage HCV-HCC versus the GALAD score, both in the overall group (0.917 vs. 0.894, P=0.057) and in the cirrhosis subgroup (0.909 vs. 0.889, P=0.132). Similar results were noted relative to the detection of early-stage HCV-HCC, whether defined by BCLC staging (stage 0-A: 0.898 vs. 0.860, P=0.026) or 8th TNM staging (stage I: 0.899 vs. 0.870, P=0.070). In subgroup analysis to detect AFP-negative HCV-HCC, the ASAP score also demonstrated a higher AUROC than the GALAD score to detect any stage HCV-HCC in the AFP-negative subgroup (0.815 vs. 0.764, P=0.063).ConclusionsThe ASAP score had better diagnostic performance for early detection of HCV-HCC compared with the GALAD score. The ASAP score may be preferrable to the GALAD score for HCC screening and surveillance among HCV-infected patients.
Author Pawlik, Timothy M.
Yin, Dong-Xu
Liang, Lei
Gu, Li-Hui
Wang, Ming-Da
Tong, Xiang-Min
Zhu, Hong
Lau, Wan Yee
Yang, Tian
Liu, Si-Yu
Shen, Feng
Sun, Li-Yang
Xing, Hao
Guan, Ming-Cheng
Li, Chao
Yao, Lan-Qing
AuthorAffiliation 6 School of Clinical Medicine, Hangzhou Medical College , Hangzhou , China
7 Eastern Hepatobiliary Clinical Research Institute (EHCRI), Third Affiliated Hospital of Navy Medical University , Shanghai , China
9 Faculty of Medicine, the Chinese University of Hong Kong, Shatin , Hong Kong, SAR , China
5 Department of Medical Oncology, the First Affiliated Hospital of Soochow University , Suzhou , China
4 Department of Hepatobiliary, Pancreatic and Minimal Invasive Surgery, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College , Zhejiang , China
2 The Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine of Zhejiang Province, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College , Hangzhou , China
8 Department of Surgery, Ohio State University, Wexner Medical Center , Columbus, OH , United States
1 Department of Laboratory Medicine, Lishui Municipal Central Hospital, the Fifth Affiliated Hospital of Wenzhou Medical Un
AuthorAffiliation_xml – name: 2 The Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine of Zhejiang Province, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College , Hangzhou , China
– name: 5 Department of Medical Oncology, the First Affiliated Hospital of Soochow University , Suzhou , China
– name: 8 Department of Surgery, Ohio State University, Wexner Medical Center , Columbus, OH , United States
– name: 3 Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University (Navy Medical University) , Shanghai , China
– name: 1 Department of Laboratory Medicine, Lishui Municipal Central Hospital, the Fifth Affiliated Hospital of Wenzhou Medical University , Lishui , China
– name: 7 Eastern Hepatobiliary Clinical Research Institute (EHCRI), Third Affiliated Hospital of Navy Medical University , Shanghai , China
– name: 9 Faculty of Medicine, the Chinese University of Hong Kong, Shatin , Hong Kong, SAR , China
– name: 4 Department of Hepatobiliary, Pancreatic and Minimal Invasive Surgery, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College , Zhejiang , China
– name: 6 School of Clinical Medicine, Hangzhou Medical College , Hangzhou , China
Author_xml – sequence: 1
  givenname: Si-Yu
  surname: Liu
  fullname: Liu, Si-Yu
– sequence: 2
  givenname: Chao
  surname: Li
  fullname: Li, Chao
– sequence: 3
  givenname: Li-Yang
  surname: Sun
  fullname: Sun, Li-Yang
– sequence: 4
  givenname: Ming-Cheng
  surname: Guan
  fullname: Guan, Ming-Cheng
– sequence: 5
  givenname: Li-Hui
  surname: Gu
  fullname: Gu, Li-Hui
– sequence: 6
  givenname: Dong-Xu
  surname: Yin
  fullname: Yin, Dong-Xu
– sequence: 7
  givenname: Lan-Qing
  surname: Yao
  fullname: Yao, Lan-Qing
– sequence: 8
  givenname: Lei
  surname: Liang
  fullname: Liang, Lei
– sequence: 9
  givenname: Ming-Da
  surname: Wang
  fullname: Wang, Ming-Da
– sequence: 10
  givenname: Hao
  surname: Xing
  fullname: Xing, Hao
– sequence: 11
  givenname: Hong
  surname: Zhu
  fullname: Zhu, Hong
– sequence: 12
  givenname: Timothy M.
  surname: Pawlik
  fullname: Pawlik, Timothy M.
– sequence: 13
  givenname: Wan Yee
  surname: Lau
  fullname: Lau, Wan Yee
– sequence: 14
  givenname: Feng
  surname: Shen
  fullname: Shen, Feng
– sequence: 15
  givenname: Xiang-Min
  surname: Tong
  fullname: Tong, Xiang-Min
– sequence: 16
  givenname: Tian
  surname: Yang
  fullname: Yang, Tian
BookMark eNp9kU1rFTEUhgepYK39Ae6ydDM1X_MRF8JwrbVwQaEK7kLm5KRNyZ1ck0yhO3-6M96LWBdmk_Ce8z45yfuyOpnihFX1mtELIXr11sUJLjjl_IJR1gvVPqtOOReyVlJ8P_nr_KI6z_meLqttKKPitPo53AxfyA3EhOQBU54zuRq2w4ej5GIiFgtC8XEi0ZE73Jvii89kUycMpqA9aBEwhDmYRMAk8FPcmXdkILs5FA84FVwLGWuIU0kxEDOZ8Jh9flU9dyZkPD_uZ9W3j5dfN5_q7eer682wrUFKXuquUchdKzt0DlpulQIuwY6GNdI2yik5wgi9Q4EKgMqxH1EaKRhTDAUdxVl1feDaaO71PvmdSY86Gq9_CzHdapOWUQPqRlHjpGX9CFaKEYyiFJhlUhghrV1Z7w-s_Tzu0K7PSyY8gT6tTP5O38YHrZquZX2zAN4cASn-mDEXvfN5_UAzYZyz5h1vFeddI5dWdmiFFHNO6P5cw6he09dr-npNXx_TXzzdPx7wxawRLtP48B_nL-bWuyo
CitedBy_id crossref_primary_10_1097_HEP_0000000000000953
crossref_primary_10_1002_jhbp_12070
crossref_primary_10_1016_j_cyto_2023_156442
crossref_primary_10_11569_wcjd_v31_i10_404
crossref_primary_10_1097_HEP_0000000000001196
crossref_primary_10_1097_HC9_0000000000000422
crossref_primary_10_1159_000536211
crossref_primary_10_2147_JHC_S499966
Cites_doi 10.1016/j.jhep.2019.08.025
10.2147/JHC.S271790
10.1053/gast.1997.v112.pm9024300
10.1016/j.jhep.2011.12.001
10.1111/j.1440-1746.2008.05487.x
10.1080/00365521.2018.1459824
10.1158/1055-9965.EPI-13-0870
10.3748/wjg.v19.i3.339
10.1158/1055-9965.EPI-18-0281
10.1053/j.gastro.2018.01.064
10.1111/j.1365-2036.2010.04370.x
10.2741/4668
10.1373/clinchem.2019.308965
10.1016/j.jhep.2021.07.004
10.1002/hep.29913
10.1159/000343847
10.1002/hep.510290424
10.1111/j.1365-2893.2009.01117.x
10.1136/gut.47.1.131
10.1111/j.1440-1746.2010.06303.x
10.1186/s12885-021-08138-3
10.1111/liv.14475
10.1002/hep4.1823
10.1016/j.jhep.2011.003
10.4254/wjh.v13.i6.699
10.1111/apt.13841
10.1007/s12072-017-9799-9
10.3322/caac.21262
10.1016/j.jhep.2011.03.019
10.21873/invivo.11413
10.3748/wjg.v20.i11.2876
10.3390/ph14080735
10.1002/(SICI)1097-0142(20000201)88:3<544::AID-CNCR8>3.0.CO;2-F
10.1111/j.1349-7006.2011.01875.x
10.1186/s12885-021-08704-9
10.20892/j.issn.2095–3941.2018.0018
10.1002/sim.5328
10.1016/j.bpg.2014.07.018
10.1016/j.cca.2013.08.005
ContentType Journal Article
Copyright Copyright © 2022 Liu, Li, Sun, Guan, Gu, Yin, Yao, Liang, Wang, Xing, Zhu, Pawlik, Lau, Shen, Tong and Yang.
Copyright © 2022 Liu, Li, Sun, Guan, Gu, Yin, Yao, Liang, Wang, Xing, Zhu, Pawlik, Lau, Shen, Tong and Yang 2022 Liu, Li, Sun, Guan, Gu, Yin, Yao, Liang, Wang, Xing, Zhu, Pawlik, Lau, Shen, Tong and Yang
Copyright_xml – notice: Copyright © 2022 Liu, Li, Sun, Guan, Gu, Yin, Yao, Liang, Wang, Xing, Zhu, Pawlik, Lau, Shen, Tong and Yang.
– notice: Copyright © 2022 Liu, Li, Sun, Guan, Gu, Yin, Yao, Liang, Wang, Xing, Zhu, Pawlik, Lau, Shen, Tong and Yang 2022 Liu, Li, Sun, Guan, Gu, Yin, Yao, Liang, Wang, Xing, Zhu, Pawlik, Lau, Shen, Tong and Yang
DBID AAYXX
CITATION
7X8
5PM
DOA
DOI 10.3389/fonc.2022.1018396
DatabaseName CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2234-943X
ExternalDocumentID oai_doaj_org_article_590af4d18bcd43bca900c1d143a34ddb
PMC9576185
10_3389_fonc_2022_1018396
GrantInformation_xml – fundername: ;
– fundername: ;
  grantid: 81972726
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
AAYXX
ACGFO
ACGFS
ACXDI
ADBBV
ADRAZ
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
DIK
EBS
EJD
EMOBN
GROUPED_DOAJ
GX1
HYE
KQ8
M48
M~E
OK1
PGMZT
RNS
RPM
7X8
5PM
ID FETCH-LOGICAL-c442t-759e2f647effc62d99c24cdba154d59f94bcbc8fe3e9cc04b8be4a431191e30b3
IEDL.DBID M48
ISSN 2234-943X
IngestDate Wed Aug 27 01:31:45 EDT 2025
Thu Aug 21 18:39:59 EDT 2025
Thu Jul 10 22:10:51 EDT 2025
Tue Jul 01 00:47:51 EDT 2025
Thu Apr 24 22:56:54 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Language English
License This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c442t-759e2f647effc62d99c24cdba154d59f94bcbc8fe3e9cc04b8be4a431191e30b3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Reviewed by: Cheng-Cheng Zhang, Army Medical University, China; Nanya Wang, First Affiliated Hospital of Jilin University, China
Edited by: Wenchuan Wu, Fudan University, China
This article was submitted to Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers, a section of the journal Frontiers in Oncology
OpenAccessLink https://doaj.org/article/590af4d18bcd43bca900c1d143a34ddb
PQID 2726922754
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_590af4d18bcd43bca900c1d143a34ddb
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9576185
proquest_miscellaneous_2726922754
crossref_primary_10_3389_fonc_2022_1018396
crossref_citationtrail_10_3389_fonc_2022_1018396
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-09-30
PublicationDateYYYYMMDD 2022-09-30
PublicationDate_xml – month: 09
  year: 2022
  text: 2022-09-30
  day: 30
PublicationDecade 2020
PublicationTitle Frontiers in oncology
PublicationYear 2022
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Singal (B1) 2020; 72
Kudo (B36) 2013; 2
Sartorius (B14) 2018; 23
Carr (B31) 2010; 25
Degos (B3) 2000; 47
Marrero (B9) 2018; 68
Yang (B22) 2019; 65
Tzartzeva (B12) 2018; 154
Torre (B2) 2015; 65
Caviglia (B13) 2018; 53
Liu (B37) 2020; 7
(B7) 2018; 69
Toshikuni (B5) 2014; 20
Svobodova (B19) 2018; 32
Gupta (B26) 2021; 21
(B25) 2012; 56
Carr (B30) 2008; 23
Hu (B10) 1999; 29
Nguyen (B17) 2009; 16
Adeniji (B39) 2021; 5
(B6) 2014; 60
Demler (B23) 2012; 31
Toyoda (B38) 2011; 102
Alazawi (B4) 2010; 32
Tarao (B27) 2021; 13
Feng (B33) 2021; 21
Rich (B18) 2014; 28
Choi (B16) 2013; 19
Loglio (B32) 2020; 40
Fattovich (B11) 1997; 112
Schotten (B35) 2021; 14
Yang (B29) 2019; 28
Omata (B24) 2017; 11
Okuda (B34) 2000; 88
Bruix (B8) 2021; 75
Li (B15) 2018; 15
Yi (B20) 2013; 425
Johnson (B21) 2014; 23
Simmons (B28) 2017; 45
References_xml – volume: 72
  year: 2020
  ident: B1
  article-title: Epidemiology and surveillance for hepatocellular carcinoma: New trends
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2019.08.025
– volume: 7
  year: 2020
  ident: B37
  article-title: Validation of the GALAD model and establishment of GAAP model for diagnosis of hepatocellular carcinoma in Chinese patients
  publication-title: J Hepatocell Carcinoma
  doi: 10.2147/JHC.S271790
– volume: 112
  year: 1997
  ident: B11
  article-title: Morbidity and mortality in compensated cirrhosis type c: a retrospective follow-up study of 384 patients
  publication-title: Gastroenterology
  doi: 10.1053/gast.1997.v112.pm9024300
– volume: 56
  year: 2012
  ident: B25
  article-title: EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2011.12.001
– volume: 23
  year: 2008
  ident: B30
  article-title: Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: a case cohort study
  publication-title: J Gastroenterol Hepatol
  doi: 10.1111/j.1440-1746.2008.05487.x
– volume: 53
  year: 2018
  ident: B13
  article-title: Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis
  publication-title: Scand J Gastroenterol
  doi: 10.1080/00365521.2018.1459824
– volume: 23
  year: 2014
  ident: B21
  article-title: The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers
  publication-title: Cancer Epidemiol Biomarkers Prev
  doi: 10.1158/1055-9965.EPI-13-0870
– volume: 19
  year: 2013
  ident: B16
  article-title: Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total- AFP
  publication-title: World J Gastroenterol
  doi: 10.3748/wjg.v19.i3.339
– volume: 28
  year: 2019
  ident: B29
  article-title: GALAD score for hepatocellular carcinoma detection in comparison with liver ultrasound and proposal of GALADUS score
  publication-title: Cancer Epidemiol Biomarkers Prev
  doi: 10.1158/1055-9965.EPI-18-0281
– volume: 154
  start-page: 1706
  year: 2018
  ident: B12
  article-title: Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: A meta-analysis
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2018.01.064
– volume: 32
  year: 2010
  ident: B4
  article-title: Systematic review: outcome of compensated cirrhosis due to chronic hepatitis c infection
  publication-title: Aliment Pharmacol Ther
  doi: 10.1111/j.1365-2036.2010.04370.x
– volume: 23
  year: 2018
  ident: B14
  article-title: The biological and diagnostic role of miRNA’s in hepatocellular carcinoma
  publication-title: Front Biosci (Landmark Ed)
  doi: 10.2741/4668
– volume: 65
  year: 2019
  ident: B22
  article-title: A novel online calculator based on serum biomarkers to detect hepatocellular carcinoma among patients with hepatitis b
  publication-title: Clin Chem
  doi: 10.1373/clinchem.2019.308965
– volume: 75
  year: 2021
  ident: B8
  article-title: Systemic treatment of hepatocellular carcinoma: An EASL position paper
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2021.07.004
– volume: 68
  year: 2018
  ident: B9
  article-title: Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases
  publication-title: Hepatology
  doi: 10.1002/hep.29913
– volume: 2
  year: 2013
  ident: B36
  article-title: Alpha-fetoprotein-L3: Useful or useless for hepatocellular carcinoma
  publication-title: Liver Cancer
  doi: 10.1159/000343847
– volume: 29
  year: 1999
  ident: B10
  article-title: The long-term outcomes of patients with compensated hepatitis c virus-related cirrhosis and history of parenteral exposure in the united states
  publication-title: Hepatology
  doi: 10.1002/hep.510290424
– volume: 16
  year: 2009
  ident: B17
  article-title: Hepatitis b-related hepatocellular carcinoma: epidemiological characteristics and disease burden
  publication-title: J Viral Hepat
  doi: 10.1111/j.1365-2893.2009.01117.x
– volume: 47
  year: 2000
  ident: B3
  article-title: Hepatitis c virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death
  publication-title: Gut
  doi: 10.1136/gut.47.1.131
– volume: 25
  year: 2010
  ident: B31
  article-title: Low alpha-fetoprotein hepatocellular carcinoma
  publication-title: J Gastroenterol Hepatol
  doi: 10.1111/j.1440-1746.2010.06303.x
– volume: 21
  start-page: 401
  year: 2021
  ident: B33
  article-title: PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma
  publication-title: BMC Cancer
  doi: 10.1186/s12885-021-08138-3
– volume: 40
  year: 2020
  ident: B32
  article-title: The combination of PIVKA-II and AFP improves the detection accuracy for HCC in HBV caucasian cirrhotics on long-term oral therapy
  publication-title: Liver Int
  doi: 10.1111/liv.14475
– volume: 5
  year: 2021
  ident: B39
  article-title: Current and emerging tools for hepatocellular carcinoma surveillance
  publication-title: Hepatol Commun
  doi: 10.1002/hep4.1823
– volume: 60
  start-page: 392
  year: 2014
  ident: B6
  article-title: EASL clinical practice guidelines: management of hepatitis c virus infection
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2011.003
– volume: 13
  start-page: 699
  year: 2021
  ident: B27
  article-title: Comparison of unenhanced magnetic resonance imaging and ultrasound in detecting very small hepatocellular carcinoma
  publication-title: World J Hepatol
  doi: 10.4254/wjh.v13.i6.699
– volume: 45
  year: 2017
  ident: B28
  article-title: Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis
  publication-title: Aliment Pharmacol Ther
  doi: 10.1111/apt.13841
– volume: 11
  year: 2017
  ident: B24
  article-title: Asia Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update
  publication-title: Hepatol Int
  doi: 10.1007/s12072-017-9799-9
– volume: 65
  start-page: 87
  year: 2015
  ident: B2
  article-title: Global cancer statistics, 2012
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21262
– volume: 69
  start-page: 182
  year: 2018
  ident: B7
  article-title: EASL clinical practice guidelines: Management of hepatocellular carcinoma
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2011.03.019
– volume: 32
  year: 2018
  ident: B19
  article-title: PIVKA-II as a potential new biomarker for hepatocellular carcinoma - a pilot study
  publication-title: In Vivo
  doi: 10.21873/invivo.11413
– volume: 20
  year: 2014
  ident: B5
  article-title: Hepatitis c-related liver cirrhosis - strategies for the prevention of hepatic decompensation, hepatocarcinogenesis, and mortality
  publication-title: World J Gastroenterol
  doi: 10.3748/wjg.v20.i11.2876
– volume: 14
  year: 2021
  ident: B35
  article-title: GALAD score detects early-stage hepatocellular carcinoma in a European cohort of chronic hepatitis b and c patients
  publication-title: Pharm (Basel)
  doi: 10.3390/ph14080735
– volume: 88
  year: 2000
  ident: B34
  article-title: Serum levels of des-gamma-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma
  publication-title: Cancer
  doi: 10.1002/(SICI)1097-0142(20000201)88:3<544::AID-CNCR8>3.0.CO;2-F
– volume: 102
  year: 2011
  ident: B38
  article-title: Clinical utility of highly sensitive lens culinaris agglutinin-reactive alpha-fetoprotein in hepatocellular carcinoma patients with alpha-fetoprotein < 20 ng/mL
  publication-title: Cancer Sci
  doi: 10.1111/j.1349-7006.2011.01875.x
– volume: 21
  start-page: 962
  year: 2021
  ident: B26
  article-title: Identifying novel transcript biomarkers for hepatocellular carcinoma (HCC) using RNA-seq datasets and machine learning
  publication-title: BMC Cancer
  doi: 10.1186/s12885-021-08704-9
– volume: 15
  year: 2018
  ident: B15
  article-title: Progress in non-invasive detection of liver fibrosis
  publication-title: Cancer Biol Med
  doi: 10.20892/j.issn.2095–3941.2018.0018
– volume: 31
  year: 2012
  ident: B23
  article-title: Misuse of DeLong test to compare AUCs for nested models
  publication-title: Stat Med
  doi: 10.1002/sim.5328
– volume: 28
  year: 2014
  ident: B18
  article-title: Hepatocellular carcinoma tumour markers: current role and expectations
  publication-title: Best Pract Res Clin Gastroenterol
  doi: 10.1016/j.bpg.2014.07.018
– volume: 425
  year: 2013
  ident: B20
  article-title: Alpha-fetoprotein-L3 in hepatocellular carcinoma: a meta-analysis
  publication-title: Clin Chim Acta
  doi: 10.1016/j.cca.2013.08.005
SSID ssj0000650103
Score 2.4025292
Snippet The GALAD and ASAP scores are two well-recognized algorithms to estimate the risk of hepatocellular carcinoma (HCC) based on gender, age, alpha-fetoprotein...
BackgroundThe GALAD and ASAP scores are two well-recognized algorithms to estimate the risk of hepatocellular carcinoma (HCC) based on gender, age,...
SourceID doaj
pubmedcentral
proquest
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Enrichment Source
Index Database
StartPage 1018396
SubjectTerms alpha-fetoprotein
diagnosis
hepatitis C virus
hepatocellular carcinoma
lens culinaris agglutinin-reactive fraction of alpha-fetoprotein
Oncology
protein induced by vitamin K absence or antagonist-II
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwELVQD4gLggJi-aiMxAkpatYZJzG30FIqRBFSqdSb5bHHaiVIEJu989PxJG61uZQLVztWHM_EfmM_vxHiLUDTokIsqOTdqrqNBZLBog5AWKLXAHwb-exrfXoBny_15U6qL-aEzfLA88AdalO6CGHdog9QoXemLP06pGXeVRAC8uyb1rydYGqegzUnMJiPMVMUZg7j0LNioVIcryZUUC8WokmvfwEylxTJnTXn5JF4mMGi7OZOPhb3qN8X98_ycfgT8ac7777Jc1ailEyv2G7kp-5Ld5yLEh6VgcaJbNXLIcorYv70eL2RR8V0iYXCXDbw_j0TUqXn3EL98NO9l52c2IbcN-KKDRWZ2C5dljJ5Ki5OPn4_Oi1ySoXCA6ixaLQhFWtoKEZfq2CMV-ADuoSkgjbRAHr0baSKjPclYIsELoGMFNZRVWL1TOz1Q0_PhaxAh2QLZ6JWbHCzRlynNq3ypgJHK1HejK_1WW-c0178sCnuYJNYNollk9hskpV4d9vk1yy2cdfDH9hotw-yTvZUkLzHZu-x__KelXhzY3Kb_isebNfTsN1Y1ajaKNVoWIlm4QuLNy5r-uurSaHbpCguAaEX_6OLL8UD_uyZo_JK7I2_t_Q6AaERDyaf_wsYogsM
  priority: 102
  providerName: Directory of Open Access Journals
Title ASAP Score versus GALAD Score for detection of hepatitis C-related hepatocellular carcinoma: A multicenter case-control analysis
URI https://www.proquest.com/docview/2726922754
https://pubmed.ncbi.nlm.nih.gov/PMC9576185
https://doaj.org/article/590af4d18bcd43bca900c1d143a34ddb
Volume 12
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3da9UwFA9zgvgifuJ1OiL4JFTb9PQjA5E63YZ4RZgX7lvJx8k2mK277YXtbX-6OW3usDAEXwrNR5vmJD2_k5z8DmNvAIpSC60jjGm1Ki9dpFHqKLeAOtYmA6DTyPPv-dECvi6z5RbbhLcKHdjdatpRPKnF6vzd5cXVRz_hP5DF6fXte9c2REYoBJmiXuHnd9hdr5gKmqfzgPbHH3NGUQ0o3JxIIZKQLsd9ztufMtFUA6H_BIVOfSj_UkoHD9mDgCZ5NYr_EdvC5jG7Nw_75U_YdXVc_eDHRFXJyf9i3fHD6lv1OSR5wMot9oM3VsNbx0-RHKz7s47vR8MpF7RjWksL_OSxyg0FH2raX2qPV3xwR6S2IWV0GAXPd64C18lTtjj48nP_KAoxFyIDIPqoyCQKl0OBzplcWCmNAGO18lDLZtJJ0Eab0mGK0pgYdKkRlEch3u7DNNbpM7bdtA0-ZzyFzMo4VtJlgkaETLROfJ1SGJmCwhmLN_1bm0BITnExzmtvmJBIahJJTSKpg0hm7O1Nld8jG8e_Cn8iod0UJCLtIaFdndRhXtaZjJUDm5TaWEi1Ub7FJrEeRaoUrNUz9noj8tpPPOps1WC77mpRiFwKUWQwY8VkLEzeOM1pzk4HCm_pzTyPlF78z_fssPt0OzqrvGTb_WqNrzwi6vXusJLgr4fLZHcY838Ave0NFg
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=ASAP+Score+versus+GALAD+Score+for+detection+of+hepatitis+C-related+hepatocellular+carcinoma%3A+A+multicenter+case-control+analysis&rft.jtitle=Frontiers+in+oncology&rft.au=Liu%2C+Si-Yu&rft.au=Li%2C+Chao&rft.au=Sun%2C+Li-Yang&rft.au=Guan%2C+Ming-Cheng&rft.date=2022-09-30&rft.issn=2234-943X&rft.eissn=2234-943X&rft.volume=12&rft_id=info:doi/10.3389%2Ffonc.2022.1018396&rft.externalDBID=n%2Fa&rft.externalDocID=10_3389_fonc_2022_1018396
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2234-943X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2234-943X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2234-943X&client=summon